Status:

COMPLETED

Development of a Molecular Diagnosing Platform for Relieving Periodontal Symptoms

Lead Sponsor:

General Biologicals Corporation

Conditions:

Periodontal Diseases

Peri-Implantitis

Eligibility:

All Genders

25+ years

Brief Summary

More than ninety percent of adults in Taiwan are suspected to carry periodontal disease, which causes bad breath, swollen and bleeding gums, plaque and even tooth loss. Half of the patients, however, ...

Eligibility Criteria

Inclusion

  • Age≧25
  • 3≦periodontal screening and recording≦4
  • 16 natural teeths and 6 front teeth at lesat
  • GI≧1.25
  • PI≧2

Exclusion

  • People who have oral lesion, dental braces, denture, mouthwash allergy, or serious systemic disease
  • People who have ever eaten antibiotics and Anti-inflammatory drugs over the last 6 months
  • People who have ever eaten Immunosuppressive drugs, antiepileptic drugs, antihypertensive drugs, or anticoagulant
  • Pregnant women or the woman who eat birth control pills

Key Trial Info

Start Date :

October 1 2015

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

September 30 2016

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT03345329

Start Date

October 1 2015

End Date

September 30 2016

Last Update

November 17 2017

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Development of a Molecular Diagnosing Platform for Relieving Periodontal Symptoms | DecenTrialz